GlassScriptPhysician profile
Reah Gambrell
NPI 1144830597
$10,427.56
in general payments reported to CMS, 2019-2025
25 companies · $3,743 in 2025
The $3,743 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,360 · 2022: $1,454 · 2023: $2,083 · 2024: $1,787 · 2025: $3,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,544 · Education: $69.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,543.82 |
| Education | $69.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,924.11 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $1,301.90 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,272.61 | 2021-2025 | Caplyta |
| Abbvie INC. | $932.63 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $617.05 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Alkermes, INC. | $505.23 | 2022-2025 | Lybalvi, Aristada |
| Corium, LLC | $494.27 | 2022-2025 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $411.40 | 2024-2025 | Cobenfy |
| Tris Pharma INC | $402.84 | 2022-2025 | Dyanavel Xr, Onyda Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $396.04 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $386.27 | 2022-2025 | Auvelity, Sunosi |
| Vanda Pharmaceuticals INC. | $289.56 | 2024-2025 | Fanapt |
| Avanir Pharmaceuticals, INC. | $219.01 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $209.72 | 2025 | Jornay Pm |
| Lundbeck LLC | $209.21 | 2021-2025 | Rexulti, Abilify Asimtufii |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $184.58 | 2021-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $176.92 | 2021-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Ironshore Pharmaceuticals INC. | $145.82 | 2022-2024 | Jornay Pm |
| Harmony Biosciences LLC | $128.23 | 2025 | |
| Sage Therapeutics, LLC | $55.48 | 2021-2024 | |
| Eisai INC. | $44.37 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $42.93 | 2022-2023 | Belsomra |
| Idorsia Pharmaceuticals US INC | $41.99 | 2023 | Quviviq |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $22.06 | 2023 | |
| Noven Therapeutics, LLC | $13.33 | 2023 | Secuado, Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reah Gambrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.